ClinicalTrials.gg
CompletedNCT05301764Updated May 20, 2026

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

A Phase 1/2 interventional study of LVGN6051 and Anlotinib in Soft Tissue Sarcoma, sponsored by Lyvgen Biopharma Holdings Limited. Completed at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Lyvgen Biopharma Holdings Limited · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing anlotinib in Sarcoma — 5 open to participants now, 6 under way, 1 of them phase 3. anlotinib · Sarcoma.

Enrollment
14th of 18
39 · median 47
Started
2022
with 1 other
Phase 1/2
3 of 18
1 open now
Registered
15th of 18
by date

Among the 18 studies testing anlotinib in Sarcoma, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1/2, and was the 15th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

5 of the 18 studies testing anlotinib in Sarcoma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing anlotinib in Sarcoma, or all of them as a file.
02

Study summary

The purpose of this study is to asess the safety and tolerability and efficacy of LVGN6051 combined with anlotinib in patient with soft tissue sarcoma.

Read the detailed description

This is a phase 1b/II, open-label, multicenter study of LVGN6051 combined with anlotinib in patients with locally advanced, metastatic or recurrent refractory soft tissue sarcoma.

The study is comprised of a dose escalation phase (Ib) to determine the RP2D and an expansion phase (II) to further explore the safety and efficacy of combination treatment.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged ≥ 18 years, who was or cytologically diagnosed unresectable locally advanced, or recurrent soft tissue sarcoma.
  2. Ability to understand and willingness to sign a written document (ICF). Informed consent of subjects must be performed before the study, and the written informed consent shall be voluntarily signed by himself or his guardian; The subject or his guardian can communicate well with the investigator, and perform according to the protocol.
  3. Performance Status (ECOG PS) of 0 or 1.
  4. Estimated , in the judgment of the Investigator, of at least 90 days.
  5. Adequate bone marrow function, as defined by all of the following:

    1. (Hb) ≥ 90 g/L, and
    2. (ANC) ≥ 1.5x109/L, and
    3. count (PLT) ≥ 75x109/L.
  6. Adequate liver function, as defined by all of the following:

    1. Total ≤ 1.5 × ; or ≤ 2.5 × ULN for patients who have serum bilirubin increases due to underlying Gilbert's Syndrome or familial benign unconjugated hyperbilirubinemia.
    2. (AST) ≤ 1.5 × ULN, and Alanine Transaminase (ALT) ≤ 1.5× ULN.
    3. (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT) ≤ 1.5×ULN, for subjects who are receiving anticoagulant therapy, INR level should be within therapeutic range.
    4. Amylase and lipase ≤1.5 × ULN
  7. Adequate renal function as defined by an estimated serum of ≥ 50 mL/min (calculated by Cockcroft-Gault formula) or serum creatinine≤1.5×ULN.
  8. Women of must agree to abstain from heterosexual intercourse or use highly effective methods from the time of signing informed consent and through 120 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she (or her partner) is participating in this study, she should inform her research physician immediately.

    a. A woman of childbearing potential is any woman, regardless of sexual orientation, who meets the following criteria: 1. has not undergone tubal ligation, a hysterectomy, or bilateral oophorectomy; or 2. has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

  9. Men enrolled on this study must agree to abstain, be surgically sterilized, or agree to use highly effective methods of contraception, including barrier contraception from the time of signing informed consent and through 120 days after the last dose of study drug.
  10. Patients should recover from all reversible AEs of previous anticancer therapies to baseline or v. 5.0 Grade 0-1, except for alopecia (any Grade), Grade \< 2 sensory or motor peripheral neuropathy, lymphopenia, or hypothyroidism on hormone replacement (Grade 2), within 14 days prior to the first dose on study. Inclusion of patients with other toxicities deemed not clinically significant (Grade ≤ 2) should be discussed and approved by the Medical Head of Sponsor.
  11. All patients must have at least one as defined by v1.1 for solid tumors.
  12. All patients with advanced/metastatic soft tissue sarcoma receiving LVGN6051 combinated with Anlotinib must have received one prior line of approved chemotherapy and disease progresses or intolerance confirmed by imaging examination before enrollment. Approved chemotherapy must include anthracycline, except acinar soft tissue sarcoma and clear cell sarcoma, which can be included in patients with recurrence or metastasis who are newly diagnosed or who only receive surgical treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy with anti-CD137 therapy.
  2. Receipt of systemic anticancer therapy including agents or devices within 5 half-lives of the first dose of study treatment. For anticancer therapies with half-life greater than 5 days, a of 28 days or longer is acceptable
  3. The subject was experienced radiotherapy within 14 days before the first dose of study treatment. [Previous radiotherapy to the central nervous system (CNS) within 28 days of the first dose of study treatment].
  4. Known unstable and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically and radiographically stable, without evidence of recurrence/progression, have no evidence of new or enlarging brain metastases or cephaledema, and are using no for at least 7 days prior to study medication.
  5. Received a live-virus vaccine within 30 days of the first dose of study drug.
  6. Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody or has a known or suspected to components of the study treatment(s).
  7. Baseline corrected by Fridericia's formula (QTcF) > 480 milliseconds or known to have congenital prolonged QT syndrome.
  8. History of Grade ≥ 3 immune-related AEs (irAEs). Exceptions: hypothyroidism, type 1 diabetes mellitus (Type 1 DM), and dermatologic irAEs (patients with previous Steven Johnson Syndrome, toxic epidermal necrolysis or other severe forms of dermatitis are ineligible) are allowed. Type 1 DM should be controlled with \<8% as per ADA recommendation.
  9. Receiving an immunologically based treatment for any reason, including chronic use of systemic steroids equivalent to > 10 mg/day of prednisone within 7 days of the first dose of study drug or at any time during study participation.

    Note: Use of inhaled or topical steroids or systemic corticosteroids equivalent to ≤ 10 mg/day prednisone equivalent is permitted as is short-term use of corticosteroids at doses equivalent to > 10 mg/day of prednisone (e.g., pre-medication prior to contrast).

  10. Treatment with systemic immune-stimulatory agents (e.g., IL-2, IFNγ) within 4 weeks prior to the first dose of study drug.
  11. History or current active or chronic disease including but not limited to inflammatory bowel disease, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease.

    Exception: Patients with vitiligo or resolved childhood asthma/atopy, hypothyroidism on stable hormone replacement, controlled asthma, Type I diabetes, Graves' disease, Hashimoto's disease, or with Medical Monitor approval.

  12. cardiac condition, including unstable angina, acute myocardial infarction within 6 months of Cycle 1 Day 1, Class III or IV congestive heart failure, unstable angina pectoris or arrhythmia requiring therapy.

    Note: A patient with an arrhythmia may enroll if the patient is on antiarrhythmic medication and is in a rate- controlled rhythm on the screening (ECG).

  13. Pleural effusion or pericardial effusion with uncontrolled or requiring repeat drainage (recurrence within two weeks after intervention), or recurrent ascites requiring drainage ≥ once a month.
  14. Active infection requiring intravenous (IV) anti-infectives within 14 days before the first dose of study treatment, or nonhealing wound or ulcer.
  15. Current evidence or history of interstitial lung disease or active, noninfectious pneumonitis requiring treatment such as oral or intravenous glucocorticoids.
  16. Female patients who are pregnant or breastfeeding (confirmation that the patient is not pregnant must be by a negative serum pregnancy test result obtained during screening; pregnancy testing is required of women of but not required for or surgically sterilized women).
  17. Any evidence of severe or uncontrolled systemic disease including, but not limited to, active bleeding diathesis, organ transplantation.
  18. Subjects with known positive test results of (HIV) or known acquired immunodeficiency syndrome (AIDS).
  19. Subjects with known active [hepatitis B surface antigen (HBsAg) positive] and / or hepatitis B core antibody (HBcAb) positive and hepatitis B virus DNA (HBV DNA) ≥ 104 copies/ml or 2000IU/ml) or virus RNA (HCV RNA) positive were known
  20. Any other disease or clinically significant abnormality in laboratory parameters, including serious medical or psychiatric illnesses/conditions, which in the judgment of the Investigator might compromise the safety of the patient, integrity of the study, interfere with the patient participation in the study, or compromise the study objectives.
  21. Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.
  22. Previous cell therapy (including but not limited to Car T cell therapy).
  23. The investigator believes subject has other acute or serious or chronic medical or psychological diseases and he is not suitable to participate in the clinical trial.
  24. Traditional Chinese medicine containing anticancer ingredients or with clear anticancer indications has been used in the past (auxiliary drugs were not included), and the elution period is 30 days.
  25. Other malignant tumors ≤5 years before the first dose. Exceptions are: early stage that have been radically cured (carcinoma in situ or stage I tumours), such as carcinoma in situ of the cervix, basal cell or squamous cell skin cancers that have been adequately treated.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    LVGN6051 combined with Anlotinib

    LVGN6051 Dose Escalation in the combination treatment with Anlotinib

    Combination Product: LVGN6051 and Anlotinib

Interventions

  • Combination productLVGN6051 and Anlotinib

    Drug pages: Exlinkibart · Anlotinib

    LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2. One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week.

06

What researchers measure

Primary outcomes

  1. To characterize the safety and tolerability of LVGN6051 combined with Anlotinib and to recommend the Phase II dose

    To evaluate the safety and tolerability of LVGN6051 combined with Anlotinib through evaluation of the frequency and severity of AEs, serious adverse events(SAEs)

    Time frame: Up to 24 months

  2. To characterize the safety and tolerability of LVGN6051 combined with Anlotinib and to recommend the Phase II dose

    To evaluate the safety and tolerability of LVGN6051 combined with Anlotinib through evaluation of the type of dose-limiting toxicities (DLTs)

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  3. to determine objective response rate (ORR) of phase II

    To assess the preliminary efficacy of LVGN6051 combined with Anlotinib in terms of objective response rate (ORR).

    Time frame: Up to 24 months

Secondary outcomes

  1. To characterize the safety and tolerability of LVGN6051 combined with Anlotinib

    To evaluate the safety and tolerability of LVGN6051 combined with Anlotinib through evaluation of the frequency and severity of AEs, Treatment-emergent Adverse Events (TEAEs), immune-related AEs (irAEs), treatment-related adverse events TRAEs), and laboratory results, Vital Signs, Physical examinations.

    Time frame: Up to 24 months

  2. To assess preliminary efficacy on overall survival (OS)(for Phase II only) using LVGN6051 combined with Anlotinib

    To assess the preliminary efficacy of LVGN6051 combined with Anlotinib in terms of overall survival (OS)(for Phase II only)

    Time frame: Up to 24 months

  3. To assess preliminary efficacy on progression-free survival (PFS) using LVGN6051 combined with Anlotinib

    To assess the preliminary efficacy of LVGN6051 combined with Anlotinib in terms of progression-free survival (PFS)

    Time frame: Up to 24 months

  4. To assess preliminary efficacy on duration of response (DoR) using LVGN6051 combined with Anlotinib

    To assess the preliminary efficacy of LVGN6051 combined with Anlotinib in terms of duration of response (DoR)

    Time frame: Up to 24 months

  5. To assess preliminary efficacy on disease control rate (DCR) using LVGN6051 combined with Anlotinib

    To assess the preliminary efficacy of LVGN6051 combined with Anlotinib in terms of disease control rate (DCR)

    Time frame: Up to 24 months

  6. To assess whether the anti-drug antibody (ADA) of LVGN6051 exist or not

    To evaluate the ADA of LVGN6051 by the number of ADA cases and incidence of ADA.

    Time frame: Up to 24 months

  7. To characterize the PK (Pharmacokinetic) profile of LVGN6051

    PK exposure parameters derived from plasma concentrations of LVGN6051

    Time frame: Up to 24 months

  8. To explore the biomarkers based on the tumor tissue sample

    To explore the correlation between biomarkers and antitumor efficacy, including PD-L1 (programmed cell death-Ligand 1), MSI/dMMR (Microsatellite Instability/Deficient Mismatch Repair), TMB (Tumor Mutation Burden).

    Time frame: Up to 24 months

  9. To explore the biomarker IL-6 (interleukin- 6) based on the serum samples.

    To explore the changes of biomarker IL-6 (interleukin- 6) after LVGN6051 and anlotinib treatment

    Time frame: Up to 15 days

  10. To explore the biomarker IL-12 (interleukin- 12) based on the serum samples.

    To explore the changes of biomarker IL-12 (interleukin- 12) after LVGN6051 and anlotinib treatment

    Time frame: Up to 15 days

  11. To explore the biomarker TNF-α (Tumor Necrosis Factor-α) based on the serum samples.

    To explore the changes of biomarker TNF-α (Tumor Necrosis Factor-α) after LVGN6051 and anlotinib treatment

    Time frame: Up to 15 days

  12. To explore the biomarker IFN-γ (Interferon Gamma) based on the serum samples.

    To explore the changes of biomarker IFN-γ (Interferon Gamma) after LVGN6051 and anlotinib treatment

    Time frame: Up to 15 days

  13. To explore the biomarker CD137 (also known as 4-1BB) based on the serum samples.

    To explore the changes of biomarker CD137 (also known as 4-1BB) after LVGN6051 and anlotinib treatment

    Time frame: Up to 15 days

07

Study locations

5 sites
  • Henan cancer hospital
    Zhenzhou, Henan 450008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality 200233, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310052, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2025, 42 months.

Of 44 industry-sponsored phase 1/2 interventional studies under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's 42 months is below that.

Counting every sponsor, half of 101 studies reached it within 62 months; a quarter within 45 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 31, 2022
StartActual
May 25, 2022
Primary completionActual
Dec 19, 2025
CompletionActual
Dec 19, 2025
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05301764
Lead sponsor
Lyvgen Biopharma Holdings Limited
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
May 25, 2022
Primary completion
Dec 19, 2025
Completion
Dec 19, 2025
Last update
May 20, 2026

Study contacts

Haiyan Hu
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exlinkibart · Anlotinib

Start the discussion